Awiqli pediatric approval brings the first weekly insulin to children with type 2 diabetes

The Awiqli pediatric approval makes Novo Nordisk's insulin icodec the first once weekly insulin cleared for children in the United States. The FDA extended the label to patients aged 10 and older with type 2 diabetes, as an add on to diet and exercise. The decision rests mainly on adult trials and a small dosing study in children, not on a pediatric efficacy trial.

What the FDA cleared

Insulin icodec is a long acting basal insulin analog designed to be injected once a week instead of once a day. According to Healio, the FDA first approved it for adults with type 2 diabetes in March 2026, making it the first weekly basal insulin in the country. The new decision, announced by Novo Nordisk on 23 October 2026, adds children aged 10 years and older with the same disease. The approved use is to improve blood sugar control alongside diet and exercise. In its notice on the pediatric approval, the agency said the application received priority review. Type 1 diabetes is not part of the new pediatric indication, and the FDA notice does not address it.

The evidence package is unusual for a first in class pediatric label. The FDA said it relied on a single dose pharmacokinetic study in 18 patients aged 10 and older. In that study, children absorbed the first injection faster than adults did. Pharmacometric modelling then showed that blood levels in children became similar to adult levels after the first few weekly injections. On that basis, the agency said it expects the drug to lower blood sugar in children in a way similar to adults. Novo Nordisk added that efficacy and safety data from its adult ONWARDS trials supported the application. In other words, adult efficacy is being extended to children through exposure matching rather than a new randomized trial in that age group.

Why a weekly insulin matters for children

Type 2 diabetes in young people tends to progress faster than in adults, and many teenagers struggle with daily injections. Eda Cengiz, who teaches pediatrics at UC San Francisco, said in Novo's press release that "children with type 2 diabetes face an aggressive disease trajectory." She argued that a weekly option "may help reduce administration barriers associated with daily insulin injections." Those are reasonable claims, but they come from a company release and from a clinician whose financial ties Healio could not confirm before publication. The label itself makes no claim about adherence, quality of life or long term outcomes in children.

The FDA said it relied on a single dose pharmacokinetic study in 18 patients aged 10 and older.

The safety warnings carry over from the adult label. The FDA lists medication errors and accidental overdose, low and high blood sugar, low potassium, and fluid retention and heart failure when the insulin is combined with thiazolidinediones. Hypoglycemia is the most common side effect, and the agency notes that severe episodes can cause seizures, loss of consciousness or death. Other common reactions include allergic reactions, skin reactions where the shot is given, changes in the fat under the skin, itching, rash, swelling and weight gain. For a once weekly product, a dosing error lasts longer than with a daily insulin. That makes training for families and clear instructions on the pen central to the Awiqli pediatric approval in practice.

The weekly insulin race

Novo is not alone in this space, and the timing of the two decisions is close. Healio reports that the pediatric decision came about a month after the FDA approved Eli Lilly's insulin efsitora alfa, sold as Onswik, as the country's second weekly basal insulin for adults. Efsitora is not approved for children, so Novo now holds the only weekly option for that group in the United States. Novo is also building a combination product that pairs icodec with semaglutide. We covered the European side of that story when the Kyinsu CHMP opinion widened the proposed EU label beyond people already on insulin or a GLP-1 drug.

These products sit at the edge of our peptide beat. Insulin is itself a peptide hormone, and weekly analogs rely on chemical changes that keep the molecule in circulation for days. For readers who follow hormone replacement drugs more broadly, the hormone pathway molecules on our board include parathyroid hormone and melanocortin agonists. The commercial stakes in children are modest compared with adults, because pediatric type 2 diabetes is a smaller population. The strategic value is different. A pediatric label lets Novo present icodec as a full family option and gives it a lead over Lilly in a group where weekly dosing may matter most.

What is still missing

The main gap is direct efficacy data in children. Exposure matching is an accepted regulatory tool, but it assumes that the disease responds the same way in teenagers as in adults once drug levels match. Given that pediatric type 2 diabetes often moves faster, real world data on blood sugar control and hypoglycemia in this age group will be important. Novo has not, in the sources we checked, described a dedicated pediatric outcomes study or registry. Weight gain, a known effect of insulin, may also matter more for adolescents who are already living with obesity, and the label offers no specific pediatric guidance on that point.

Practical use raises its own questions. Children's weight and insulin needs change as they grow, and a weekly product leaves less room to adjust quickly than a daily one. Pharmacists and diabetes teams will need clear rules for switching from daily basal insulin and for handling missed doses. None of this undermines the approval, but it shapes how widely it will be used. The Awiqli pediatric approval is best read as an access step backed by modelling, not as new evidence that weekly insulin works better in young people. Further data from clinical use should show whether the modelling holds up.

Conclusion

The Awiqli pediatric approval gives children aged 10 and older with type 2 diabetes the first weekly basal insulin in the United States. It rests on adult trials and an 18 patient dosing study. The next checkpoints are real world safety data, any pediatric decision for Lilly's efsitora and the progress of icodec combinations.